Malin Corporation Plc

Board/Management Information • Apr 8, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4662V

Malin Corporation PLC

08 April 2019

Malin Corporation plc

("Malin")

Kymab appoints Simon Sturge as Chief Executive Officer

-     Malin owns approximately 8% of Kymab, a Malin Priority Asset -

Dublin-Ireland, 8 April 2019: Malin Corporation plc (Euronext Growth Dublin:MLC), a company investing in highly innovative life sciences companies, is pleased to note that Kymab, one of Malin's Priority Assets, has appointed pharmaceutical veteran, Simon Sturge, as its Chief Executive Officer, effective 1 May 2019.

Simon Sturge will join from Merck KGaA, where he was Executive Vice President Global Strategy, Business Development & Global Operations. Previously, he was Chief Operating Officer of Merck Healthcare, responsible for the company's global commercial and manufacturing operations. Over the past five years, he has been responsible for the continued growth in global sales at Merck KGaA, as well as the commercial launches of products, including BAVENCIO® (anti-PD-L1 avelumab) in solid tumours and MAVENCLAD® (cladribine) for relapsing multiple sclerosis.  

"Simon Sturge's appointment as CEO of Kymab strengthens the company's management team at a crucial time for Kymab when the company has two clinical-stage lead candidates in development," said Jean-Michel Cosséry, Non-Executive Director of Malin and Malin's Kymab Board designate. "Simon's extensive clinical, regulatory, business development and commercial knowledge and experience will greatly benefit the company across all stages of its maturity. At the same time, we note David Chiswell's significant contribution and leadership of Kymab over the past many years and thank him."

Malin owns approximately 8% of Kymab and carried its investment in Kymab at a fair value estimate of €28.7 million at 31 December 2018 under International Private Equity and Venture Capital Valuation guidelines.

A copy of Kymab's press release is available to view here:

https://www.kymab.com/news-and-events/news/2019/apr/8/kymab-appoints-simon-sturge-ceo/

ENDS

For further information, please contact:

Malin

Jessica Bergin, Director of Investor Relations & External Reporting

Tel: +353 (0)1 901 5700

investorrelations@malinplc.com

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson

Tel: +44 (0)20 3709 5700

malin@consilium-comms.com

Powerscourt (Irish media enquiries)              

Eavan Gannon                                              

Tel: +353 87 236 5973                            

malin@powerscourt-group.com                                                                          

Davy Corporate Finance (ESM Adviser)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in and supporting highly innovative life sciences companies developing exceptional science and technology to deliver transformative outcomes for patients and create significant value for shareholders. Its purpose is to create shareholder value through the application of long-term capital and strategic support to its investee companies to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ISESSAFFAFUSEFL